Centessa Pharmaceuticals (CNTA) to Release Quarterly Earnings on Wednesday

Key Points

• Centessa will report Q1 2026 results before the open on Wednesday, May 13, with analysts expecting earnings of ($0.38) per share
• The stock recently opened around $39.67 with a market cap of $5.92 billion and a 12‑month range of $10.95–$40.26, and carries a consensus analyst rating of "Hold" with a $40.70 price target.
• Insiders sold 309,112 shares (about $8.42M) over the last three months while institutional investors own roughly 82.01% of Centessa, indicating strong institutional backing amid insider reductions.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) will likely be announcing its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter. Investors may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 7:00 AM ET.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.10). On average, analysts expect Centessa Pharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Centessa Pharmaceuticals Stock Down 0.1%

Shares of Centessa Pharmaceuticals stock opened at $39.67 on Wednesday. The company has a fifty day moving average price of $33.17 and a 200 day moving average price of $27.94. The company has a current ratio of 8.57, a quick ratio of 8.57 and a debt-to-equity ratio of 0.21. Centessa Pharmaceuticals has a twelve month low of $10.95 and a twelve month high of $40.26. The stock has a market cap of $5.92 billion, a price-to-earnings ratio of -26.99 and a beta of 1.13.

Wall Street Analysts Forecast Growth

CNTA has been the subject of a number of analyst reports. Guggenheim cut shares of Centessa Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, April 2nd. Stephens cut shares of Centessa Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, March 31st. Truist Financial cut shares of Centessa Pharmaceuticals from a "buy" rating to a "hold" rating and set a $38.00 price objective for the company. in a research report on Monday, April 13th. Needham & Company LLC cut shares of Centessa Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Tuesday, March 31st. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Centessa Pharmaceuticals in a research report on Monday, April 20th. Four analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $40.70.

Insider Transactions at Centessa Pharmaceuticals

In other news, insider Karen M. Anderson sold 120,029 shares of the company's stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $26.25, for a total value of $3,150,761.25. Following the sale, the insider owned 62,085 shares in the company, valued at approximately $1,629,731.25. This represents a 65.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Gregory M. Weinhoff sold 73,196 shares of the company's stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $26.33, for a total transaction of $1,927,250.68. Following the completion of the sale, the insider owned 65,925 shares in the company, valued at approximately $1,735,805.25. This trade represents a 52.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 309,112 shares of company stock valued at $8,424,535. 7.09% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of institutional investors have recently modified their holdings of CNTA. Braidwell LP acquired a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at about $54,730,000. Maverick Capital Ltd. acquired a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at about $41,110,000. Adage Capital Partners GP L.L.C. raised its stake in shares of Centessa Pharmaceuticals by 20.8% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,403,000 shares of the company's stock valued at $110,415,000 after purchasing an additional 1,449,000 shares in the last quarter. Balyasny Asset Management L.P. acquired a new stake in shares of Centessa Pharmaceuticals in the 2nd quarter valued at about $16,052,000. Finally, Farallon Capital Management LLC raised its stake in shares of Centessa Pharmaceuticals by 24.1% in the 4th quarter. Farallon Capital Management LLC now owns 5,377,068 shares of the company's stock valued at $134,480,000 after purchasing an additional 1,045,750 shares in the last quarter. Institutional investors and hedge funds own 82.01% of the company's stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.